Achieving and maintaining optimal glycemic control necessitates the long-term administration of various glucose-lowering drugs for individuals with T2DM, including thiazolidinediones, dipeptidyl peptidase IV inhibitors, glucagon-like peptide-1 analogues, insulin/insulin analogues, sodium-glucose cotransporter inhibit, sulfonylureas, and metformin [2, 3]. This evidence concerns the gene INS and type 2 diabetes mellitus.